Study | A clearly stated aim | Inclusion of consecutive patients | Prospective collection of data | Endpoints appropriate to the aim of the study | Unbiased assessment of the study endpoint | Follow-up period appropriate to the aim of the study | Loss to follow-up less than 5% | Prospective calculation of the study size |
---|---|---|---|---|---|---|---|---|
Yu [16] | 2 | 2 | 2 | 2 | 0 | 1 | 2 | 0 |
Qiu [17] | 2 | 2 | 2 | 2 | 0 | 1 | 2 | 0 |
Luo [18] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 |
Haijun [19] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 |
Oshima [20] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 |
Liu [13] | 2 | 2 | 2 | 2 | 0 | 1 | 2 | 0 |
Zhang [21] | 2 | 2 | 2 | 2 | 0 | 1 | 2 | 0 |
Ross [22] | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 |
Zhang [23] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 |
Siemionow [24] | 2 | 2 | 2 | 2 | 0 | 2 | 1 | 0 |
Yadav [25] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 |
Dahdaleh [14] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 |
Yabuki [26] | 2 | 2 | 2 | 2 | 0 | 1 | 2 | 0 |
Adamson [32] | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 0 |